Immunotherapy, which recruits the body’s own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease. But many cancer immunotherapy treatments can be expensive, have devastating side effects, and only work in a fraction of patients.
Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have developed a new therapeutic vaccine that uses a patient’s own tumor cells to train their immune system to find and kill cancer.
The vaccine, which is injected into the skin just like a traditional vaccine, stopped melanoma tumor growth in mice. It even worked long-term, destroying new tumors long after the initial injection… Continue reading.
Today it was announced that Melody Swartz, William B. Ogden Professor of Molecular Engineering at the Pritzker School of Molecular Engineering (PME) at the University of Chicago, has been elected to membership in the National Academy of Medicine.
Swartz holds a joint appointment in the Ben May Department for Cancer Research and serves as deputy dean for faculty affairs at Pritzker Molecular Engineering. She is also a co-founder of the Chicago Immunoengineering Innovation Center (CIIC). Her research interests include lymphatic physiology, cancer research, and immunotherapy… Continue reading.
Multiple sclerosis, an autoimmune disease of the central nervous system that affects millions worldwide, can cause debilitating symptoms for those who suffer from it.
Though treatments exist, researchers are still searching for therapies that could more effectively treat the disease, or even prevent it altogether.
Researchers at the Pritzker School of Molecular Engineering (PME) at the University of Chicago have designed a new therapy for multiple sclerosis (MS) by fusing a cytokine to a blood protein. In mice, this combination prevented destructive immune cells from infiltrating the central nervous system and decreased the number of cells that play a role in MS development, leading to fewer symptoms and even disease prevention… Continue reading.
Immunotherapy, which unleashes the power of the body’s own immune system to find and destroy cancer cells, has shown promise in treating several types of cancer.
But the disease is notorious for cloaking itself from the immune system, and tumors that are not inflamed and do not elicit a response from the immune system—so-called “cold” tumors—do not respond to immunotherapies.
Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have taken a step toward solving this problem with an innovative immunotherapy delivery system. The system finds tumors by seeking out and binding to the tumors’ collagen, then uses a protein called IL-12 to inflame the tumor and activate the immune system, thereby activating immunotherapy… Continue reading.